If you live or work on the 103rd floor of a building, chances are you ride the elevator up to your pad.
Not Zac Vawter—not, at least, on Sunday. Yesterday, the 31-year-old amputee wore a prototype prosthetic and successfully climbed 103 stories up the Willis Tower in Chicago, scaling 2,109 steps to a height of 1,353 feet.
Vawter’s climb was the first public showing of a new kind of prototype prosthetic that is controlled, in part, by electrical impulses traveling from his brain. Vawter took 45 minutes to finish the climb, the AP reports. His goal had been one hour, the Chicago Tribune reported a few days earlier.
The ten-pound artificial leg is being developed by a team led by Levi Hargrove from at the Center for Bionic medicine at the Rehabilitation Institute of Chicago.
Nerves from Vawter’s amputated leg were re-attached to his hamstring in an early operation. It’s those nerves that controlled the mechanical bits on his leg. “Targeted muscle reinnervation,” a technique Hargrove has described as “rewiring the patient,” is what allows the prosthetic to function as it does. Electrodes on Vawter’s thigh translate the neuron signals to electrical instructions that move the leg.
The Skyrise Chicago event at the 110-story Willis Tower is organized by the Rehabilitation Institute. The funds participants raise each year are directed toward research and training at the Institute.
For Vawter, the stairmaster prosthetic is a temporary accessory. He’ll leave it behind in Chicago for further development when he returns home to Yelm, Washington, but the leg’s builders hope for a wider release in the near future.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.